African Nations Plan Regional Bioequivalence Testing
A new framework aims to cut costs and drug approval times by establishing local capacity for testing generic medicines.
Updated on Oct. 24, 2026 in Biotech
Live Poll
Do you believe localizing pharmaceutical manufacturing in your region will make medicine more affordable?
Stakeholders recently concluded a five-day workshop in Addis Ababa to establish a regional framework for bioequivalence testing in Eastern and Southern Africa. This proposal aims to shift pharmaceutical oversight away from a heavy reliance on overseas testing facilities for generic medicine approval.
Why it matters
The initiative seeks to eliminate the high costs and regulatory delays currently associated with external testing for regional manufacturers. By developing shared local capacity, the region hopes to improve the accessibility and safety verification of generic pharmaceuticals.
The proposed strategy involves implementing phased, risk-based compliance pathways for legacy products. The framework replaces the current dependence on international testing with shared regional infrastructure governed by new oversight mechanisms.
The players
Intergovernmental Authority on Development
A regional trade bloc that manages economic integration and development policy across East African nations.
World Bank
A global financial institution providing capital and technical expertise for infrastructure and health system improvements.
The details
Bioequivalence testing — a process that confirms two drugs deliver the same active ingredients to the bloodstream at the same rate — currently forces African manufacturers to export samples to overseas labs. Experts in Addis Ababa proposed building regional testing capacity to handle this verification domestically. This approach intends to replace costly, fragmented international logistics with a harmonized, risk-based regulatory pipeline for generic drugs.
Timeline
October 19, 2026: The workshop on bioequivalence testing began in Addis Ababa.
October 23, 2026: The regional workshop concluded.
The Tech Race
This move towards regional autonomy follows a growing trend of developing localized health infrastructure to decrease dependence on global supply chains. It parallels broader efforts to standardize regulatory practices across the continent to accelerate generic drug approvals.
Regional manufacturers may see reduced regulatory approval times and lower operational costs once the proposed testing framework is implemented. Access to affordable, verified generic medicines for patients depends on the speed at which these new regional facilities become operational.
The takeaway
The region is moving toward a centralized model to lower the barrier for generic drug certification. Observers should track the ratification of these oversight mechanisms and the subsequent funding announcements for the planned shared testing facilities.
Further reading
For broader analysis on how regulatory changes influence the Biotech landscape, explore our dedicated research section.
Source note: This article includes information reported by News.
Live Poll
Do you believe localizing pharmaceutical manufacturing in your region will make medicine more affordable?
